Rivaroxaban: A review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism

Drugs

Volumn 74, Issue 2, 2014, Pages 243-262

  Burness, Celeste B ^a   Perry, Caroline M ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; CARBAMAZEPINE; CLOPIDOGREL; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; ENOXAPARIN; ITRACONAZOLE; KETOCONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PLACEBO; POSACONAZOLE; PROTHROMBIN; RIFAMPICIN; RITONAVIR; RIVAROXABAN; THROMBIN; TICLOPIDINE; VORICONAZOLE; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; ANTICOAGULANT THERAPY; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; HUMAN; HYPERTRANSAMINASEMIA; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MODERATE HEPATIC IMPAIRMENT; NAUSEA; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PROTHROMBIN TIME; PRURITUS; QT INTERVAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; STEADY STATE; TABLET FORMULATION; TACHYCARDIA; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; PULMONARY EMBOLISM; SECONDARY PREVENTION; VENOUS THROMBOSIS;

ANTICOAGULANTS; FACTOR XA INHIBITORS; HUMANS; MORPHOLINES; PULMONARY EMBOLISM; SECONDARY PREVENTION; THIOPHENES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84895755847     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0174-4     Document Type: Article

References (92)

1. Turpie AG, Esmon C. Venous and arterial thrombosis: pathogenesis and the rationale for anticoagulation. Thromb Haemost. 2011;105(4):586-96.
2. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl 2):e419S-94S.
3. National Institute for Health and Clinical Excellence. CG144 Venous thromboembolic disease: NICE guideline. 2012. http://guidance.nice.org.uk/CG144/ NICEGuidance/pdf/English. Accessed 13 Dec 2013.
4. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe: the number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756-64.
5. Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(Suppl 4):S495-501.
6. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205.
7. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med. 2004;164(1):17-26.
8. Abad Rico JI, Llau Pitarch JV, Paramo Fernandez JA. Topical issues in venous thromboembolism. Drugs. 2010;70(Suppl 2):11-8.
9. ®: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000944/WC500057108.pdf. Accessed 13 Dec 2013.
10. National Institute for Health and Clinical Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. 2012. http://www.nice.org.uk/nicemedia/live/ 13805/60040/60040.pdf. Accessed 13 Dec 2013.
11. ® (rivaroxaban): US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2013/022406s004lbl.pdf. Accessed 13 Dec 2013.
12. Duggan ST. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery. Am J Card Drugs. 2012;12(1):57-72.
13. Duggan ST, Scott LJ, Plosker GL. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs. 2009;69(13):1829-51.
14. Carter NJ, Plosker GL. Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Drugs. 2013;73(7):715-39.
15. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3(3):514-21.
16. Tersteegen A, Burkhardt N. Rivaroxaban an oral, direct factor Xa inhibitor binds rapidly to factor Xa [abstract no. P-W-651]. J Thromb Haemost. 2007;5(Suppl):2.
17. Laux V, Perzborn E, Kubitza D, et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost. 2007;33(5):515-23.
18. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]- 1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005;48(19):5900-8.
19. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol. 2007;47(11):1398-407.
20. Perzborn E, Harwardt M. Inhibition of thrombin generation in human plasma by rivaroxaban, an oral, direct factor Xa inhibitor [abstract no. PP-MO-184]. J Thromb Haemost. 2009;7(Suppl 2):379.
21. Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost. 2007;5(4):886-8.
22. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116(2):180-7.
23. Varin R, Mirshahi S, Mirshahi P, et al. Effect of rivaroxaban, an oral direct factor Xa inhibitor, on whole blood clot permeation and thrombolysis: critical role of red blood cells [abstract no. 1064]. 51st ASH Annual Meeting and Exposition; 5-8 Dec 2009; New Orleans, LA.
24. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412-21.
25. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-80.
26. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther. 2007;45(6):335-44.
27. Mueck W, Lensing AWA, Agnelli G. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675-86.
28. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703-12.
29. Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89-98.
30. Perzborn E, Lange U. Rivaroxaban: an oral, direct factor Xa inhibitor inhibits tissue factor-mediated platelet aggregation [abstract no. P-W-642]. XXI ISTH Congress; 6-12 Jul 2007; Geneva.
31. Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban-an oral, direct factor Xa inhibitor-has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol. 2008;143(1):92-9.
32. Kubitza D, Mueck W, Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf. 2008;31(1):67-77.
33. European Medicines Agency. Xarelto-H-C-000944-X-0010: EPAR: Assessment Report - Variation 2011. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Assessment-Report-Variation/human/000944/WC500120736.pdf. Accessed 13 Dec 2013.
34. Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol. 2006;46(9):981-90.
35. Kubitza D, Becka M, Mueck W, et al. Rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63(4):469-76.
36. Kubitza D, Becka M, Mueck W, et al. Co-administration of rivaroxaban: a novel, oral direct factor Xa inhibitor - and clopidogrel in healthy subjects [abstract no. P1272]. Eur Heart J. 2007;28(Suppl 1):189.
37. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(5):549-58.
38. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009;37(5):1056-64.
39. Kubitza D, Becka M, Roth A, et al. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban: an oral, direct factor Xa inhibitor. J Clin Pharmacol. 2013;53(3):249-55.
40. Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47(2):218-26.
41. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66.
42. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the EINSTEIN-DVT dose-ranging study. Blood. 2008;112(6):2242-7.
43. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510.
44. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97.
45. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013. doi: 10.1186/1477-9560-11-21.
46. Prins M, Bamber L, Cano S, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism [abstract no. 1163]. 54th ASH Annual Meeting and Exposition; 8-11 Dec 2012; Atlanta, GA.
47. Prins M, Erkens P, Lensing A. Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies [abstract no. OC 79.4]. XXIV Congress of the International Society on Thrombosis and Haemostasis; 29 Jun-4 Jul 2013; Amsterdam.
48. Prins MH, Bounameaux H, Lensing A, et al. The effect of prerandomization use of therapeutic anticoagulants on the risk of recurrent venous thromboembolism in patients with deep vein thrombosis treated with rivaroxaban [abstract no. P-TH-286]. J Thromb Haemost. 2011;9(Suppl 2):860.
49. Prins MH, Lensing AWA, Wells P, et al. The relative efficacy of rivaroxaban vs. vitamin K antagonists (VKA) in relation to time in therapeutic range (TTR) in patients with deep vein thrombosis (DVT) [abstract no. P-TH-281]. J Thromb Haemost. 2011;9(Suppl 2):858.
50. Bamber L, Wang MY, Prins MH, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost. 2013. doi: 10.1160/TH13-03-0243.
51. European Medicines Agency. Xarelto-H-C-944-II-18: EPAR: Assessment Report - Variation 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Assessment-Report-Variation/human/000944/WC500138505.pdf. Accessed 13 Dec 2013.
52. Wasserlauf G, Grandi SM, Filion KB, et al. Meta-analysis of rivaroxaban and bleeding risk. Am J Cardiol. 2013;112(3):454-60.
53. Davidson B, Verheijen S, Lensing A, et al. Risk of bleeding in patients with acute venous thromboembolism treated with rivaroxaban or enoxaparin/VKA and concomitant ASA therapy or NSAIDs: subanalysis from EINSTEIN DVT and PE studies [abstract no. AS 17.1]. XXIV Congress of the International Society on Thrombosis and Haemostasis; 29 Jun-4 Jul 2013; Amsterdam.
54. Seaman CD, Smith KJ, Ragni MV. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective. Thromb Res. 2013. doi: 10.1016/j.thromres.2013.09.015.
55. National Institute for Health and Clinical Excellence. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. 2013. http://www.nice.org.uk/nicemedia/live/14192/64274/64274.pdf. Accessed 13 Dec 2013.
56. Lefebvre P, Coleman CI, Bookhart BK, et al. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ. 2013. doi: 10.3111/13696998. 2013.858634.
57. ®) SMC No. (852/13). 2013. http://www. scottishmedicines.org.uk/files/advice/rivaroxaban-Xarelto-FINAL-FEBRUARY-2013- amended-04.03.13-for-website.pdf. Accessed 13 Dec 2013.
58. McLeod E, Guillermin A, Hudson R, et al. Cost-effectiveness of rivaroxaban for the treatment of pulmonary embolism and secondary prevention of venous thromboembolism: a UK perspective [abstract no. OC 02.6]. XXIV Congress of the International Society on Thrombosis and Haemostasis; 29 Jun-4 Jul 2013; Amsterdam.
59. Becattini C, Agnelli G, Emmerich J, et al. Initial treatment of venous thromboembolism. Thromb Haemost. 2006;96(3):242-50.
60. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl 2):e44S-88S.
61. Hutten BA, Lensing AW, Kraaijenhagen RA, et al. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging. 1999;14(4):303-12.
62. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-8.
63. Gogarten W, Vandermeulen E, Van Aken H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27(12):999-1015.
64. Rosencher N, Llau JV, Mueck W, et al. Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiol Scand. 2013;57(5):565-72.
65. Bayer. Treatment of an acute deep vein thrombosis (DVT) with either rivaroxaban or current standard of care therapy (XALIA) [ClinicalTrials.gov identifier NCT01619007]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://clinicaltrials.gov/ct2/show/NCT01619007. Accessed 13 Dec 2013.
66. Thrombosis Research Institute. About GARFIELD VTE. 2013. http://www.tri-london.ac.uk/uploads/files/GARFIELD%20VTE%20Study%20Overview.pdf. Accessed 13 Dec 2013.
67. Donadini MP, Ageno W, Douketis JD. Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach. Drugs. 2012;72(15):1965-75.
68. Fareed J, Sadeghi N, Kahn D, et al. Tissue factor mediated activation of prothrombin complex concentrates (PCCs) is differently inhibited by dabigatran, rivaroxaban and apixaban: potential clinical implications [abstract no. 3410]. 54th ASH Annual Meeting and Exposition; 8-11 Dec 2012; Atlanta, GA.
69. Godier A, Miclot A, Le Bonniec B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2012;116(1):94-102.
70. Gruber A, Marzec UM, Buetehorn U, et al. Reversal of the antihaemostatic effects of rivaroxaban by activated factor VII and activated prothrombin complex in primates [abstract no. 3825]. American Society of Hematology (ASH) 50th Annual Meeting and Exposition; Jun 2009; San Francisco, CA.
71. Gruber A, Marzec UM, Buetehorn U, et al. Activated factor VII and activated prothrombin complex for reversal of the antihaemostatic effects of rivaroxaban in primates [abstract no. 80]. Br J Haematol. 2009;145(Suppl S1):32.
72. Hollenbach S, Lu G, Tan S, et al. PRT064445 but not recombinant FVIIa reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model [abstract no. 3414]. 54th ASH Annual Meeting and Exposition; 8-11 Dec 2012; Atlanta, GA.
73. Perzborn E, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats [abstract no. PP-MO-183]. XXII ISTH Congress; 11-16 Jul 2009; Boston, MA.
74. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573-9.
75. Levi M, Moore T, Castillejos C, et al. Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban [abstract no. OC 36.5]. XXIV Congress of the International Society on Thrombosis and Haemostasis; 29 Jun-4 Jul 2013; Amsterdam.
76. Portola Pharmaceuticals. Phase 2 healthy volunteer study to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests [ClinicalTrials.gov identifier NCT01758432]. US National Institutes of Health, ClinicalTrials.gov. 2012. http://clinicaltrials.gov/ct2/ show/NCT01758432. Accessed 13 Dec 2013.
77. Crowther M, Mathur V, Kitt M. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors [abstract no. 3636]. 55th ASH Annual Meeting and Exposition; 7-10 Dec 2013; New Orleans, LA.
78. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol. 2012;159(4):427-9.
79. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban: an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103(4):815-25.
80. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107(2):379-87.
81. Brandjes DP, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327(21):1485-9.
82. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293(6):681-9.
83. Boehringer Ingelheim Limited. Pradaxa: summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000829/WC500041059.pdf. Accessed 13 Dec 2013.
84. ® (dabigatran etexilate mesylate capsules): US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022512s017lbl.pdf. Accessed 13 Dec 2013.
85. ® (apixaban) Summary of Product Characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/002148/WC500107728.pdf. Accessed 13 Dec 2013.
86. Daiichi Sankyo Company Ltd. Daiichi Sankyo receives first market approval in Japan for LIXIANA(R) (edoxaban), a direct oral factor Xa inhibitor, for the prevention of venous thromboembolism after major orthopedic surgery [media release]. 22 Apr 2011. http://www.daiichisankyo.com/media-investors/media- relations/press-releases/detail/005806.html.
87. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52.
88. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.
89. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15.
90. Wong PC, Crain EJ, Watson CA, et al. Comparative antithrombotic and antihemostatic effects of the direct factor Xa inhibitors, apixaban and rivaroxaban, and the direct thrombin inhibitors, dabigatran and lepirudin, in rabbit models of venous thrombosis and bleeding time [abstract no. 3025]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9 2008; San Francisco, CA.
91. Fox BD, Kahn SR, Langleben D, et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ. 2012;345:e7498.
92. Sardar P, Chatterjee S, Mukherjee D. Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials. Drugs. 2013;73(11):1171-82.